Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07602582 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

StatusRecruiting
PhasePhase 3
Started2026-05-22
View on ClinicalTrials.gov ↗
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

Amendment history 3 changes detected by DataLookout

2026-06-27
Recruitment opened
2026-06-27
Trial sites expanded: 53 → 58 locations
2026-06-27
Completion moved earlier: 2029-12 → 2029-09
Trial Details
NCT Number NCT07602582
Lead Sponsor Eli Lilly and Company
Conditions Alzheimer Disease, Dementia, Plaque, Amyloid
Enrollment 550 participants
Start Date 2026-05-22
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-07